Processing

Please wait...

Settings

Settings

Goto Application

1. IN201721019625 - PREPARATION AND EVALUATION OF SOLID LIPID NANO PARTICLES FOR CANCER TREATMENT.

Office India
Application Number 201721019625
Application Date 05.06.2017
Publication Number 201721019625
Publication Date 12.07.2019
Publication Kind A
IPC
A61K 1/00
Applicants SANKHA BHATTACHARYA
Inventors BHUPENDRA GOPAL BHAI PRAJAPATI
Title
(EN) PREPARATION AND EVALUATION OF SOLID LIPID NANO PARTICLES FOR CANCER TREATMENT.
Abstract
(EN)
ABSTRACT:Glioblastoma Multiforme (GBM) is the most common solid malignant tumour in the central nervous system. Which accounts almost 40% of brain tumours, GBM forms satellites of tumours along with frequent occurrence and poor prognosis. The biggest challenge for brain drug delivery is insurmountable Blood Brain Barrier (BBB).To succumb this problem a new indigenous novel approach called Bovine Serum Albumin(BSA) and Anti-Epithelial Growth Factor(Anti-EGFR),conjugated cationic Solid Lipid Nanoparticles (SLNs) was introduced. SLNs have a very narrow particle size (10-1000 nm) with higher cellular uptake. The aim of present research work was to develop and evaluate less then lOOnm particle sized; cationic Solid Lipid Nanoparticles (SLNs) for GBM treatment. In present research work, Solid Lipid Nanoparticles(SLNs) were prepared using Cyclophosphamide as a model drug, Glycerol Monostearate and Stearic Acid as lipids, Methanol as an organic solvent, Poloxamer 188, Cetrimide, Brij 78 and Tween 80 as surfactants and Soya Lecithin as co-surfactant. The melt dispersion and high share homogeneous techniques were used to prepare SLNs. The prepared SLNs were then evaluated and characterized by PXRD, FTIR, DSC, zeta potential, polydispersity index, drug entrapment efficacy, viscosity, in-vitro drug release studies. The optimized batch (SLN27) was assayed using Reverse Phase-Ultra High Performance Liquid Chromatography (RP-UHPLC) method. The optimized batch (SLN27) was further lyophilised and conjugates with Cationic Bovine Serum Albumin (CBSA) and Anti-EGFRl -Tyr-1175 monoclonal antibody to form Anti-EGFR-CBSA-CYP-SLNs. The Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE) verified the conjugations in Anti-EGFR-CBSA-CYP-SLNs formulation. Further, the obtained product was lyophilised and MTT cytotoxicity studies were carried out by taking B16F10 cell line. Moreover, lymphocyte toxicity studies, in-vitro anticancer activity studies using C57BL mice model, haemolytic studies, in-vitro transendothelial transport studies, cellular uptake studies, fluorescence microscopic studies in U-87MG cell lines(Cell line of GBM), in-vitro drug release studies and six-months stability studies were also performed. From the result outcomes, it is obvious that it is possible to make a target-specific drug delivery system by considering solid lipid imrnunoconjugates based nano particular approach for brain cancer treatment, specifically for Glioblastoma Multiforme (GBM) treatment. REFERENCES:1. Yung-Chih Kuo, Cheng -Te Liang. Inhibition of human brain malignant glioblastoma cells using carmustine-loaded cationic solid lipid nanoparticles with a surface anti-epithelial growth factor. Biomaterials 32 (2011) 3340-33502. Xin-Hua Tian, Xiao-Ning Lin, Feng Wei, Wei Feng, Zhi-Chun Huang, Peng Wang, Lei Ren, Yi Diao. Enhanced brain targeting of Temozolomide in polysorbate-80 coated poly butyl cyanoacrylate nanoparticles. International Journal of Nanomedicine. 6 (2011) 445-452.3. Abhinav Agarwal, SaiJkat Majumder, Himanshu Agrawal, Subrata Majumdar, Govind P. Agrawal. Canonized albumin conjugated solid lipid nanoparticles as vectors for brain delivery of an anti-cancer drug. Current Nanoscience.7 (2011) 71-80.4. Tiffany E. Taylor, Frank B. Furnari, Webster K. Cavenee. Targeting EGFR for Treatment of Glioblastoma: Molecular Basis to Overcome Resistance. Curr Cancer Drug Targets. 12 (3)(2012)197-209.5. Manigauha, A., Kharya, M.D., Ganesh, N., 2015. In vivo antitumor potential of Ipomoea pes-caprae on melanoma cancer. Pharmacogn Mag. 11(42), 426-433.6. Byron SA, Gartside MG, Wellens CL, Mallon MA, Keenan JB and Powell MA. Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation. Cancer Res. 2008; 68:6902-6907.7. Vitthal D. Dhakane;Milind B.Ubale .Development and validation of a reverse phase high performance liquid chromatographic method for the estimation of Cyclophosphamide in bulk drug. International journal of pharmacy and pharmaceutical science. 2013,Vol 5 ,supply 2. Available at: http://www.iirpbsonline.com/archives6.html